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ABSTRACT
Objectives: The development of long-acting, injectable atypical antipsy-
chotics has provided a new paradigm for schizophrenia treatment. The
study was designed to assess whether a risperidone long-acting injection
(RLAI) is associated with reduced relapses and service utilization in the
real world.
Methods: The Psychiatric Inpatients Medical Claims dataset was used for
the analysis. It is a longitudinal dataset that includes the National Health
Insurance claims of service uses by a cohort of mentally ill patients. The
inclusion criteria for this analysis were patients who: 1) had available
information for at least 12 months after the ﬁrst dose of RLAI; 2) had a
primary diagnosis of schizophrenia; and 3) were regularly treated with
RLAI for at least 1 year. Patients who accumulatively received at least
75-mg RLAI per 3-month period were considered to be undergoing regular
treatment. Wilcoxon signed rank tests were performed to compare
differences in numbers of acute admissions, hospital days, emergency
room visits, and relapses between the pre- and post-RLAI periods in this
1-year mirror-image study.
Results: In total, 108 patients were eligible for analysis. Signiﬁcant reduc-
tions in the total annual numbers of acute hospital admissions by 55% (80
vs. 36, P = 0.0003), hospital days by 48% (4106 vs. 2126, P = 0.0021),
and relapses by 54% (115 vs. 53, P = 0.0005) were observed. A reduction
of emergency room visits was also observed, but did not reach statistical
signiﬁcance (55 vs. 25, P = 0.1255).
Conclusions: This 1-year mirror-image analysis with claims-based data
demonstrated that RLAI treatment was associated with reductions in
relapses and hospital service utilization.
Keywords: National Health Insurance, relapse, risperidone long-acting
injection, schizophrenia, Taiwan.
Introduction
Schizophrenia is a debilitating illness resulting in signiﬁcant costs
for as much as 3% of total health–care expenditure [1], primarily
a reﬂection of the frequent need for inpatient or other intensive
emergent services required to manage acute relapses which are
often related to poor compliance [2]. Indeed, relapses lead to
acute admissions, deterioration of health status, functioning [3,4]
adverse neurological sequela [5], and disease chronicity [2].
Achieving good compliance to antipsychotic medications for
patients with schizophrenia remains the most challenging issue
for relapse prevention. For example, patients receiving anti-
psychotics took an average of only 58% of the recommended
amount of the medications [6], although it is slightly less an issue
for newer than for older antipsychotic agents found in recent
studies [7]. It is striking to ﬁnd that, in the recent landmark
Clinical Antipsychotic Trials of Intervention Effectiveness study,
74% of trial participants discontinued the study medication
before the planned 18 months [8]. Discontinuation and poor
compliance to antipsychotic medications potentially lead to a
disease relapse and an increase of hospital utilization. For
example, in the classic studies of maintenance antipsychotic
medication from a Veterans Administration study of schizophre-
nia, the relapse rate for inpatients randomly assigned to receive
placebo was 15% per month, as compared to 1.5% per month
of relapse rate for inpatients assigned to receive continuous
medication [9,10]. Interestingly, the relapse rate for outpatients
assigned to receive continuous medication was slightly higher
(3–5% per month) [9,10] than that for inpatients (1.5% per
month), implying that an increased unreliability in medication
taking (noncompliance) from inpatient to outpatient settings can
make difference in disease relapse [11].
Because relapses in patients with schizophrenia are associated
with poor outcome and prognosis, the improvement of medica-
tion compliance becomes a major issue when dealing with relapse
prevention [12]. Long-acting injection of antipsychotics is a valu-
able strategy to improve medication compliance, and hence,
could potentially improve treatment outcomes [12]. Recent clini-
cal trials and mirror-image studies support that the oral route of
administration results in a higher risk of relapse than depot
injections. For example, a systematic review with randomized-
controlled clinical trials on comparing oral and depot forms of
conventional antipsychotic medications revealed that the 1-year
relapse rate was 42% for oral administration compared with
27% for the depot route [11]. Mirror-image studies, in which
each patient acts as his/her own control, of long-acting injection
of conventional antipsychotics have shown signiﬁcant decreases
of numbers and days of hospitalization. For example, in Denham
and Adamson’s study, enrolling 103 patients with chronic schizo-
phrenia who were currently receiving either ﬂuphenazine enan-
thate or decanoate, the number of hospitalizations was reduced
by 73% and the number of days of hospitalization by 82% after
patients’ switching from oral to depot administrations [13].
The development of second-generation antipsychotics (SGA)
has provided a new treatment paradigm because of their superior
tolerability and efﬁcacy [14–16], and in some cases, cost-
effectiveness [17,18]. In addition, a recent study by Dolder et al.
also showed that medication compliance was better with SGA
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than ﬁrst-generation antipsychotics (FGA) in schizophrenia
patients [7]. Speciﬁcally, outpatients receiving haloperidol or per-
phenazine (FGA) were without medication for approximately 7
days per month, although patients receiving risperidone, olanza-
pine, or quetiapine (SGA) were without medication for approxi-
mately 4 days per month. Risperidone long-acting injection
(RLAI) is the ﬁrst licensed long-acting injectable SGA and was
recently reported to be cost effective in reducing the total admis-
sion numbers and inpatient days in a mirror-image analysis from
a community-based inpatient setting [19]. A study from Chang
et al. based on national claim-based database reported prelimi-
nary results on changes in hospital service utilization among a
sample of patients in Taiwan who regularly used RLAI for 6
months but changes in relapses were not reported [20]. In this
study, we tested the hypothesis that RLAI can reduce 1-year
relapses and hospital service utilization in a mirror-image analy-




The data for this study were obtained from the Psychiatric Inpa-
tients Medical Claims Data (PIMC) compiled from claims data of
the NHI program and released by the National Health Research
Institutes, Taiwan. The NHI claims database contains nationwide
population-based data. It provides comprehensive information on
health-care resource utilization bymore than 21million enrollees,
representing about 97% of the Taiwanese population. The PIMC
contains longitudinal data from January 1, 1996 to December 31,
2006 of a cohort of 91,104 mentally ill patients who were
admitted to hospitals by psychiatry departments with ICD-9-
codes 230–319 or A-codes A210–A219 during 1996–2001.
Study Subjects
From June 1, 2004, the NHI program began to include the RLAI
in its formulary. To the end of 2006, 1449 patients had been
prescribed RLAI. The index date was deﬁned as the date of the
outpatient/emergency visit, or the discharge date of the hospital-
ization, when RLAI was prescribed for the ﬁrst time. The inclu-
sion criteria for study subjects in this study were patients who: 1)
could be observed for at least 1 year before the index date
(pre-RLAI periods); 2) had a primary diagnosis of schizophrenia
(ICD-9-CM code 295) at the index visit/hospitalization; and 3)
were regularly treated with RLAI for at least 1 year (post-RLAI
periods). Patients who received at least 75-mg RLAI every 3
months were considered to be undergoing regular treatment (see
Fig. S1 at Relapse and Long-Acting Injectable Risperidone: A
1-Year Mirror Image Study with a National Claims Database in
Taiwan at Value in Health, Supporting Information at: http://
www.ispor.org/Publications/value/ViHsupplementary/ViH12s3_
Tang2.asp. for the selection process for study subjects).
The ﬁnal sample available for analysis was 108 patients.
Because the average hospital stay for single acute psychiatric
hospitalization was 33 days in Taiwan in 2007, a secondary
analysis excluding patients who had long hospital stays (90 days
per acute ward admission) in either period was conducted to
minimize the possible impact of extreme cases of prolonged
hospitalization. The sample available for this secondary analysis
was 91 patients.
Outcome Measurement
Health-care utilization in 12 months before the initial RLAI use
(the pre-RLAI period) and in 12 months after the initial RLAI use
(the post-RLAI period) was compared. Speciﬁc health-care utili-
zation measures were numbers of acute admissions, hospital
days, emergency room (ER) visits, and relapses. The number of
relapses was deﬁned as the sum of number of admissions and ER
visits. Nevertheless, admissions and emergency visits occurred
within 2 days were considered as the same episode of care and
were deﬁned as one relapse.
Statistical Analyses
Wilcoxon signed rank tests were performed to compare differ-
ences in the numbers of acute admissions, hospital days, ER
visits, and relapses between the pre- and post-RLAI periods in
this 1-year mirror-image study. All analyses were performed
using the SAS/STAT system for Windows, version 9.01 (SAS
Institute, Cary, NC, USA).
Results
There were 108 subjects eligible for analysis, and their charac-
teristics are reported in Table S1 (see Table S1 at Relapse and
Long-Acting Injectable Risperidone: A 1-Year Mirror Image
Study with a National Claims Database in Taiwan, Value in
Health, Supporting Information at: http://www.ispor.org/
Publications/value/ViHsupplementary/ViH12s3_Tang2.asp). The
mean age was 42.01  10.44 (range, 20.67–67.44) years. The
mean dose of RLAI in the post-RLAI period was
175.44  54.47 mg per 3-month period. None of them had
received more than one dosage of typical long-acting injectable
antipsychotics in the pre-RLAI period. More than three quarters
of the subjects (78.70%) were on monotherapy before their
switching to RLAI, among them, about two-thirds (68.23%)
were on SGAs and one-third (31.77%) were on FGAs. Among
those who were on SGAs, about 30% were using oral risperi-
done. About 13.89% of subject received both SGAs and FGAs
medication at the same time.
In Table S2, the Wilcoxon signed tests showed that number of
acute admissions, number of hospital days, and number of
relapses were signiﬁcantly lower in the 1-year pre-RLAI period
than those in the 1-year post-RLAI period. In the secondary
analysis, the case number was slightly decreased (n = 91), but
differences in acute admissions, hospital days, and relapses
remained signiﬁcant (see Table S2 at Relapse and Long-Acting
Injectable Risperidone: A 1-Year Mirror Image Study with a
National Claims Database in Taiwan, Value in Health, Support-
ing Information at http://www.ispor.org/Publications/value/
ViHsupplementary/ViH12s3_Tang2.asp). A reduced number of
emergency room visits was observed in both the primary and the
secondary analyses, but did not reach statistical signiﬁcance.
Table S3 showed that, compared to the 1-year pre-RLAI
period, the total annual number of acute admissions was reduced
by 55% (80 vs. 36), total hospital days were reduced by 48%
(4106 vs. 2127), and numbers of relapses were reduced by 54%
(114 vs. 53) in the 1-year post-RLAI period (see Table S3 at
Relapse and Long-Acting Injectable Risperidone: A 1-YearMirror
Image Study with a National Claims Database in Taiwan, Value
in Health, Supporting Information at: http://www.ispor.org/
Publications/value/ViHsupplementary/ViH12s3_Tang2.asp). A
reduced number of ER visits was also observed (55 vs. 25), but did
not reach statistical signiﬁcance. The secondary analysis showed
similar reducing patterns in the health-care resource use before
and after the initial use of RLAI.
Discussion
In this 1-year mirror-image study using a national claims-based
database in Taiwan, we found that RLAI was associated with
reductions in relapses and hospital service utilization, measured
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by days of hospital stays, and numbers of acute admissions and
ER visits, in patients with schizophrenia. This implies that there
might be a correlation between a positive treatment outcomes
and improved medication compliance by changing from oral to
injectable antipsychotics. Our ﬁndings, using a national claims-
based database, are consistent with previous mirror-image
studies comparing oral and depot forms of ﬂuphenazine
[13,21,22] or risperidone [19] using data from hospital settings.
In mirror-image studies, a period before an index event, in our
case the starting date of RLAI treatment, can be compared with a
period of equal length after that event. The strength of thismethod
is that each patient serves as his/her own control. Nevertheless, the
advantage of long-acting injectable agents can be overestimated
due to: 1) the selection bias (e.g., the long-acting injection was
begun when previous treatments failed, and the including criteria
might be too restricted and rule out many patients; 2) the changes
in service delivery may be associated with administration of the
RLAI rather than RLAI itself (e.g., enhanced follow-up after the
implementation of a new treatment); 3) the natural disease course
of tending stabilization; and 4) the exclusion of patients with
partial compliance in traditional mirror-image studies conducted
in clinical settings (e.g., patients who lost some of their psychiatric
follow-up were not included in certain study appointments). With
the claims-based database, we can mildly minimize the latter bias
by obtaining most of the data meeting the minimal requirement in
the database. In this study, we used an including criteria of
“receiving at least 75 mg RLAI every three-month period,” which
is a relatively ﬂexible criterion because the usual dose of RLAI is
25 to 50 mg every 2 weeks according to the US Prescribing
Information. The dosage of risperidone in treating schizophrenia
has been found to be lower in Taiwan than that in theUnited States
[23]. Therefore, criteria with this low dose of RLAI might not be
irrelevant in clinical practice in Taiwan.
There were some other limitations in our study. First, the
PIMC database only includes patients admitted for psychiatric
inpatient care between January 1, 1996 and December 31, 2001,
which would result in the exclusion of schizophrenic patients
with only outpatient service use during that time period. Second,
the lack of control group is associated with some other draw-
backs. Oral medications in the pre-RLAI period being not con-
trolled; hence, the better outcomes in the post-RLAI period could
have been due to medication effects rather than effects of the
drug form. In addition, the medication prescription patterns may
differ by hospital level, physician personal preference, and shift-
ing policy. Third, although acute hospitalizations and ER visits as
outcome measurement of relapse for schizophrenia have good
face validity [24], the real number of relapses might have been
underestimated. Furthermore, the meaning and entity of “acute
hospitalizations” might translate poorly among different health-
care contexts [24]. Finally, it is not available for the speciﬁc
information on side effects, clinical status, patient types, or the
real drug compliance because of the entity of the study design
with national claims database. Because of these methodological
limitations, the reductions in the numbers of relapses and hospi-
tal service utilization could not be attributed to RLAI on its own.
For the future study, a prospective clinical trial in clinical settings
or a case-controlled design using the claim data are warranted for
generalizability and to provide more information across nations
on the comparison of the effect of RLAI use on relapse for the
patients with schizophrenia.
Conclusion
In conclusion, this 1-year mirror-image analysis showed that
RLAI treatment is associated with reductions in the numbers of
relapses and hospital service utilization in Taiwan, and further
investigations are warranted for long-term outcomes, including
costs.
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